Please login to the form below

Not currently logged in
Email:
Password:

Versartis names chief financial officer

Joshua Brumm joins from Pharmacyclics

Versartis has named Joshua Brumm as its first chief financial officer.

Brumm joins from Pharmacyclics where he was principal financial officer and executive VP of finance.

He already has life sciences financial experience, having previously served as chief financial officer for Zeltiq Aesthetics and director of finance at Proteolix.

In his new role at Versartis, Brumm will lead the company's financial operations as it prepares to for the commercialisation of its phase III prospect VRS-317, which is in development as a treatment for growth hormone deficiency.

The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will significantly strengthen our management team."

18th December 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....